20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT01906489
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT01906489
-
- Other papers using this trial's data
- Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01906489. Randomized; quadruple masking; primary purpose treatment. Start 2013-07-23 (actual); primary completion 2014-09-03 (actual). Results posted on 2022-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- Condition
- Anemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- AKB-6548
- Intervention (Drug)
- Placebo
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct01906489- Content hash
8002802e14a14eab3f705b33944f681ba820d520302ebc35c1a5b13d5e7abca8